Safety Study of Autologous Cultured Adipose -Derived Stem Cells for the Fecal Incontinence

This study has been terminated.
(Few subject enrolled)
Information provided by:
Anterogen Co., Ltd. Identifier:
First received: November 10, 2009
Last updated: March 8, 2011
Last verified: March 2011

Fecal incontinence affects 18.4% adults in the community and greatly impacts quality of life. There's a problem like inconvenience, pain or allergic response in many therapeutic methods such as a surgical operation or material injection. ANT-SM is autologous adipose-derived stem cell, and so, expect of no immune responses. In this study, patients are given injection of ANT-AM in anal sphincter and followed for 4 weeks to test the safety.

Condition Intervention Phase
Fecal Incontinence
Biological: ANT-SM
Phase 1

Study Type: Interventional
Official Title: A Phase I Clinical Study of ANT-SM (Autologous Cultured Adipose-derived Stem Cell) for the Treatment of Fecal Incontinence to Evaluate Safety

Resource links provided by NLM:

Further study details as provided by Anterogen Co., Ltd.:

Primary Outcome Measures:
  • Efficacy: Wexner's score evaluation [ Designated as safety issue: Yes ]
  • Safety: Clinically measured abnormality of laboratory tests and adverse events [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Anorectal manometry and endorectal ultrasound at week 4

Arms Assigned Interventions
Experimental: ANT-SM
autologous adipose-derived stem cell
Biological: ANT-SM
autologous adipose-derived stem cell


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Older than 18 years
  • Wexner's fecal incontinence score > or egal 5
  • patient who has fecal incontinence for more than 6 months
  • Continuity of anal sphincter at endorectal ultrasound and abnormality of anal function at anorectal manometry
  • negative for urine beta-HCG for woman of childbearing age
  • agreement to participate, with signed informed-consent

Exclusion Criteria:

  • Anorectal surgery within the last 6 months prior to the study
  • patient who is allergy to bovine-derived materials and an anesthetic
  • patients with a diagnosis of auto immune disease
  • Diagnosis of HBV, HCV, HIV and other infectious disease
  • Patients with a diagnosis of active Tuberculosis
  • Patient is pregnant or breast-feeding
  • Women within 6 months post partum
  • Patient who is unwilling to use an "effective" method of contraception during the study
  • Patients with a diagnosis of Inflammatory Bowel Disease
  • Patient who has a clinically relevant history of abuse of alcohol or drugs
  • Insufficient adipose tissue for manufacturing of ANT-SM
  • Patient whom investigator consider is not suitable in this study
  • Patients have history of surgery for malignant cancer in the past 5 years
  • Patient who has to undergo ano-rectal surgery
  • Patient who has a history of artificial anal sphincter surgery
  • Patient who has taken cytotoxic drugs within the last 30 days
  • Patient whom investigator consider is not suitable in this study reasons for severe ano-rectal disease, severe constipation, fistula, rectal prolapsed or neurological diseases (spinal cord injury, multiple sclerosis, Parkinson's disease)
  Contacts and Locations
Please refer to this study by its identifier: NCT01011686

Korea, Republic of
Seoul National University Hospital
Seoul, Korea, Republic of, 110-744
Sponsors and Collaborators
Anterogen Co., Ltd.
  More Information

No publications provided Identifier: NCT01011686     History of Changes
Other Study ID Numbers: ANT-SM-101
Study First Received: November 10, 2009
Last Updated: March 8, 2011
Health Authority: Korea: Food and Drug Administration

Additional relevant MeSH terms:
Fecal Incontinence
Rectal Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases processed this record on April 17, 2014